Synergistic anti-tumor effect of recombinant human endostatin adenovirus combined with gemcitabine

Anti-Cancer Drugs

Volumn 16, Issue 5, 2005, Pages 551-557

  Wu, Yang ^a   Yang, Li ^a   Hu, Bing ^a   Liu, Ji Yan ^a   Su, Jing Mei ^a   Luo, Yan ^a   Ding, Zhen Yu ^a   Niu, Ting ^a   Li, Qiu ^a   Xie, Xing Jiang ^a   Wen, Yan Jun ^a   Tian, Ling ^a   Kan, Bing ^a   Mao, Yong Qiu ^a   Wei, Yu Quan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Chemotherapy; Endostatin; Gemcitabine; Gene therapy

Indexed keywords

CARBOPLATIN; ENDOSTATIN; GEMCITABINE; PACLITAXEL; THALIDOMIDE;

ADENOVIRUS; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LOW DRUG DOSE; LUNG CARCINOMA; MICROVASCULATURE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG SYNERGISM; ENDOSTATINS; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRALESIONAL; INJECTIONS, INTRAPERITONEAL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 21044446644     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200506000-00011     Document Type: Article

References (25)

1. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastasis: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1:149-153.
2. Gasparini G. The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs 1999; 58:17-38.
3. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277-285.
4. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
5. Spiro SG, Porter JC. Lung cancer - where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med 2002; 166:1166-1196.
6. van Moorsel CJA, Pinedo HM, Veerman G, Vermerken JB, Postmus PE, Peters GJ. Scheduling of gemcitabine and cisplatin in Lewis lung tumor bearing mice. Eur J Cancer 1999; 35:808-814.
7. Brock CS, Lee SM. Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer. Eur Respir J 2002; 19:557-570
8. Sauter BV, Martinet O, Zhang WJ, Mandeli J, Woo SLC. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci USA 2000; 97:4802-4807.
9. Bello L, Carrabba G, Giussani C, Lucini V, Cerutti F, Scaglione F, et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 2001; 61:7501-7506.
10. He TC, Zhou SB, DA Costa LT, YU J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95:2509-2514.
11. Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, Mcconkey DJ, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000; 6:1936-1948.
12. Dings RPM, Yokoyama Y, Ramakrishnan S, Griffioen AW, Mayo KH. The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Res 2003; 63:382-385.
13. Herbst RS, Hidalgo M, Pierson AS, Holden SN, Bergen M, Eckhardt SG. Angiogenesis inhibition in clinical development for lung cancer. Semin Oncol 2002; 29:66-77.
14. Feldman AL, Restifo NP, Alexander HR, Bartlett DL, Hwu P, Seth P, et al. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res 2000; 60: 1503-1506.
15. Reimer CL, Agata N, Tammam JG, Bamberg M, Dickerson WM, Kamphaus GD, et al. Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis. Cancer Res 2002; 62:789-795.
16. Morioka H, Weissbach L, Vogel T, Nielsen GP, Faircloth GT, Shao L, et al. Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis. Clin Cancer Res 2003; 9:1211-1217.
17. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000; 105;1045-1047.
18. Vartanian RK, Weidner N. Endothelial cell proliferation in prostatic carcinoma and prostatic hyperplasia: correlation with Gleason's score, microvessel density, and epithelial cell proliferation. Lab Inves 1995; 73:844-850.
19. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen JZ, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001; 61:3369-3372.
20. Miller KD, Sweeney CJ, Sledge GW. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001; 19:1195-1206.
21. Mishima K, Mazar AP, Gown A, Skelly M, Ji XD, Wang XD, et al. A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc Natl Acad Sci USA 2000; 97;8484-8489.
22. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105:R15-R24.
23. Klement G, Huang P, Mayer B, Green SK, Man S, Bohlen P, et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug resistant human breast cancer xenografts. Clin Cancer Res 2002; 8:221-223.
24. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, et al. antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60:1878-1886.
25. Marx GM, Steer CB, Harper P, Pavlakis N, Rixe O, Khayat D. Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock. J Clin Oncol 2002; 20:1446-1448.